AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung cancer. | Following an FDA approval last year based on a tumor progression ...

AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its blockbuster cancer drug Tagrisso (osimertinib) for expanded use ...

Positive high-level results have been presented from the final overall survival (OS) analysis of the FLAURA2 Phase III trial.

(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable ...

AstraZeneca noted that Tagrisso is approved for patients with EGFR mutations in the 1st-line metastatic setting as a monotherapy and in combination with chemotherapy, ...

AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...

AstraZeneca Plc. announced on Monday that it plans to invest $50 billion in the U.S. by 2030, with a focus on expanding drug ...